Amgen Inc: (NSDQ: AMGN)

(U.S: NSDQ) As of Jul 31, 2014 04:00 PM ET

 Add to portfolio

$127.39 USD

-2.62 (-2.02%)

Volume: 4,661,419

Zacks Rank : 3-Hold [?]     3    

Brokerage Reports

Search for reports:

0 items in cart

AMGEN INC [AMGN]

Reports for Purchase

Showing records 1 - 20 ( 180 total )

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 1

07/31/2014

Company Report

Pages: 10

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 2

06/25/2014

Industry Report

Pages: 6

Biotechnology -May Institutional Data Gives a Look into Q214

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 25.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 3

05/21/2014

Industry Report

Pages: 7

Biotechnology - First Look at Q214 with April Script Data

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 25.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 4

05/06/2014

Company Report

Pages: 11

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 5

04/23/2014

Company Report

Pages: 8

A Q1 Miss Usually No Big Deal, but This One More Bothersome

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 25.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 6

04/23/2014

Company Report

Pages: 10

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 7

04/23/2014

Industry Report

Pages: 6

Just in Time - March Script Data Offers One More Glimpse At Q114

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 25.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 8

03/31/2014

Industry Report

Pages: 5

PCSK9 on Full Display at ACC, No Surprises Here

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 10.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 9

03/19/2014

Industry Report

Pages: 6

February Script Data Tempered by Fewer Selling Days

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 25.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 10

02/28/2014

Company Report

Pages: 10

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 11

01/30/2014

Company Report

Pages: 9

Price: 24.95

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 12

01/29/2014

Financial Spreadsheet

Pages: 24

Model.

Provider: Nomura

Analyst: SOMAIYA M

Price: .00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 13

01/29/2014

Company Report

Pages: 8

One-Timers Once Again; Guidance Just Okay

Provider: Robert W. Baird & Co., Inc.

Analyst: RAYMOND C

Price: 25.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 14

01/28/2014

Company Report

Pages: 10

4Q13 Beat Not Followed by a Raise

Provider: Nomura

Analyst: SOMAIYA M

Price: 25.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 15

01/23/2014

Company Report

Pages: 5

Another Positive P3 Readout for Evolocumab

Provider: Nomura

Analyst: SOMAIYA M

Price: 10.00

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 16

01/15/2014

Financial Spreadsheet

Pages: 24

Model.

Provider: Nomura

Price: .00

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 17

01/13/2014

Company Report

Pages: 8

Reducing Estimates to Reflect Higher SG&A

Provider: Nomura

Price: 25.00

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 18

01/09/2014

Financial Spreadsheet

Pages: 24

Model.

Provider: Nomura

Price: .00

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 19

01/09/2014

Daily Note

Pages: 14

Previewing 4Q13 and 2014 Guidance

Provider: Nomura

Price: 50.00

Research Provided by a Third Party

Company: AMGEN INC

Industry: MED-BIOMED/GENE

Record: 20

01/07/2014

Company Report

Pages: 46

Initiating with Neutral Rating and $131 TP

Provider: Nomura

Price: 100.00

Research Provided by a Third Party